[Study of protective properties of recombinant atoxic form of exotoxin A and recombinant outer membrane protein F of Pseudomonas aeruginosa].
OBJECTIVE
To obtain recombinant atoxic form of Pseudomonas aeruginosa exotoxin A and assess its protective properties during simultaneous administration with recombinant protein F in experiment.


METHODS
Genetic methods were employed for construction of deletion variant of P. aeruginosa exotoxin A gene, whereas Escherichia coli cells were used for transformation. Purification of proteins was performed by common method. White outbred mice were used for immunization and experimental infection was produced by intraperitoneal administration of live virulent culture of P. aeruginosa strain PA103.


RESULTS
The gene coding defect form of P. aeruginosa exotoxin A with lacked 106 C-terminal aminoacid residues was cloned. Synthesized protein was nontoxic and immunogenic. Recombinant variants of anatoxin A and outer membrane protein F of P. aeruginosa protected animals from experimental infection caused by toxigenic strain PA103 of P. aeruginosa if were administered separately or concomitantly. Nonetheless, the highest protective effect was observed after immunization with both proteins.


CONCLUSIONS
Studied recombinant toxoid and OprF could be the candidates for inclusion in vaccines for prevention of pseudomonas infection.
Mikhaĭlova
N A
NA
Vertiev
Iu V
IuV
Kaloshin
A A
AA
Isakov
M A
MA
D036002:ADP Ribose Transferases / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D001427:Bacterial Toxins / Q000008:administration & dosage / Q000276:immunology*; D005098:Exotoxins / Q000008:administration & dosage / Q000276:immunology*; D007274:Injections, Intraperitoneal; D051379:Mice; D018272:Porins / Q000008:administration & dosage / Q000276:immunology*; D011552:Pseudomonas Infections / Q000517:prevention & control*; D054406:Pseudomonas Vaccines / Q000008:administration & dosage / Q000276:immunology*; D011550:Pseudomonas aeruginosa / Q000737:chemistry / Q000276:immunology*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology*; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D037521:Virulence Factors / Q000008:administration & dosage / Q000276:immunology*; D000097668:Pseudomonas aeruginosa Exotoxin A
D036002:ADP Ribose Transferases; D001427:Bacterial Toxins; D005098:Exotoxins; D018272:Porins; D054406:Pseudomonas Vaccines; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A; C109237:OmpF protein